Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Iza-bren
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed

Sponsor

Bristol-Myers Squibb